Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons
Authors:
- Charles JoussainCJCharles Joussain
- Olivier Le CozOCOlivier Le Coz
- Andrey PichuginAPAndrey Pichugin
- Peggy MarconiPeggy Marconi
- Filip LimFLFilip Lim
- Mariaconcetta SicurellaMSMariaconcetta Sicurella
- Andrea SaloniaASAndrea Salonia
- Francesco MontorsiFMFrancesco Montorsi
- Francisco WandosellFrancisco Wandosell
- Keith FosterKFKeith Foster
- François GiulianoFGFrançois Giuliano
- Alberto L. EpsteinAEAlberto L. Epstein
Open Access
Abstract
A set of herpes simplex virus type 1 (HSV-1) amplicon vectors expressing the light chains (LC) of botulinum neurotoxins (BoNT) A, B, C, D, E and F was constructed. Their properties have been assessed in primary cultures of rat embryonic dorsal root ganglia (DRG) neurons, and in organotypic cultures of explanted DRG from adult rats. Following infection of primary cultures of rat embryonic DRG neurons, the different BoNT LC induced efficient cleavage of their corresponding target Soluble N-ethylmaleimide-sensitive-factor Attachment protein Receptor (SNARE) protein (VAMP, SNAP25, syntaxin). A similar effect was observed following infection by BoNT-A LC of organotypic cultures of adult rat DRG. To quantify and compare the functional activities of the different BoNT LC, the inhibition of calcitonin gene-related protein (CGRP) secretion was assessed in DRG neurons following infection by the different vectors. All BoNT-LC were able to inhibit CGRP secretion although to different levels. Vectors expressing BoNT-F LC displayed the highest inhibitory activity, while those expressing BoNT-D and -E LC induced a significantly lower CGRP release inhibition. Cleavage of SNARE proteins and inhibition of CGRP release could be detected in neuron cultures infected at less than one transducing unit (TU) per neuron, showing the extreme efficacy of these vectors. To our knowledge this is the first study investigating the impact of vector-expressed transgenic BoNT LC in sensory neurons.Keywords
Funding Information
- Eranet Neuron (N° ANR-16-NEU3-003)
- Wings for Life - Spinal Cord Research Foundation (WFL-FR-07/17 – N°154)
- ANR-France (ANR-10-IBHU-0006)
This publication has 55 references indexed in Scilit:
- Gene therapy for pain: Results of a phase I clinical trialAnnals of Neurology, 2011
- Novel tumour‐specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectorsThe Journal of Gene Medicine, 2010
- N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomersJournal of Neurochemistry, 2010
- Refractory Idiopathic Urge Urinary Incontinence and Botulinum A InjectionJournal of Urology, 2008
- SNAREs — engines for membrane fusionNature Reviews Molecular Cell Biology, 2006
- Characterization of antiproliferative and cytotoxic properties of the HSV‐1 immediate‐early ICP0 proteinThe Journal of Gene Medicine, 2005
- Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1Journal of Molecular and Cellular Cardiology, 2005
- Update on herpesvirus amplicon vectorsMolecular Therapy, 2004
- Improved Packaging System for Generation of High-Level Noncytotoxic HSV-1 Amplicon Vectors Using Cre-loxP Site-Specific Recombination to Delete the Packaging Signals of Defective Helper GenomesHuman Gene Therapy, 2003
- Cleavage of Vesicle-Associated Membrane Protein (VAMP)-2 and Cellubrevin on GLUT4-Containing Vesicles Inhibits the Translocation of GLUT4 in 3T3-L1 AdipocytesBiochemical and Biophysical Research Communications, 1996